Nyhet från partner

Asgard’s CEO on the EUR 30 million Series A financing

Asgard’s CEO on the EUR 30 million Series A financing

Asgard Therapeutics is a biotech based in Lund developing an immune “Trojan horse” to defeat cancer.

The company recently announced a € 30 million Series A financing to advance its cell reprogramming platform for immuno-oncology. Asgard’s CEO and co-founder Cristiana Pires stopped by the BioStock Studio to tell us all about it.

Lorem ipsum dolor sit amet. Est omnis iusto eos velit nostrum et pariatur quod non. Consequuntur nemo id dolores tempora ut quis quis eum. Porro dolore rem voluptas iste. Consequuntur nemo id dolores tempora ut quis quis eum

Denna källa har få eller inga artiklar bakom betalvägg
Läs hela texten hos Biostock

Nyhetsbrev